An investigation for investors in NASDAQ:IRWD shares over potential securities laws violations by Ironwood Pharmaceuticals in connection certain financial statements was announced.
Investors who purchased shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) concerning whether a series of statements by Ironwood Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Cambridge, MA based Ironwood Pharmaceuticals, Inc. is a biotechnology company. On April 26 2016, a report alleged that contrary to Ironwood Pharmaceuticals’ claims, Linzess’s side effects are not limited to the gastrointestinal (GI) tract, but are instead causing” previously unknown, unreported and unlabeled severe systemic adverse events, including documented cases of rapid weight gain, renal failure, seizures and strokes. Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) declined on April 26, 2016, to as low as $9.06 per share.
On May 6, 2016, NASDAQ:IRWD shares closed at $10.02 per share.
Those who purchased NASDAQ:IRWD shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego